Latest Health Technology News

Cardiex Limited reported a 10% revenue increase in FY25, driven by new product launches and significant cost reductions, positioning the company for growth in FY26 with strong backing from C2 Ventures.

Hydrix Limited narrowed its FY2025 loss to $2.92 million, driven by significant cost reductions and steady revenue from expanding international medtech clients. Despite ongoing challenges in sales cycles and funding, the company remains focused on innovation and strategic investments.

MedAdvisor Limited reported a staggering $60.2 million loss for FY25, driven by operational challenges and asset impairments, while divesting its ANZ business and becoming debt-free.

Audeara Limited reported a 19% revenue increase to $3.79 million for FY25, driven by strong Australian wholesale growth and expanding international partnerships. Despite a net loss of $1.79 million, the company’s AUA Technology division and new licensing deals position it for future profitability.

Audeara Limited reports a strong start to FY26 with a 46% revenue increase driven by Australian wholesale growth and a key international partnership. The company’s global ambitions are further highlighted by multiple export award nominations.

Audeara Limited has secured a five-year licensing agreement with Eastech (Huizhou) Co., Ltd. to bring its advanced hearing technology to China’s booming medical device market, leveraging major e-commerce platforms for distribution.

Pro Medicus Limited has entered a strategic financing arrangement with 4DMedical to accelerate the development and commercialization of cutting-edge lung function imaging software.

Advanced Health Intelligence Ltd has locked in up to AUD 5.5 million from Oakley Capital Partners, reinforcing its capital base as it pushes toward reinstatement on the ASX and broader growth ambitions.

InteliCare Holdings reported a $564,000 operating cash outflow in Q4 2025 and has secured $1 million in additional funding to support ongoing operations despite a cash runway under one quarter.

TrivarX has secured key approvals and begun recruiting for its innovative mental health screening trial in US veterans, while also launching a wearable tech pilot with a Major League Baseball academy in the Dominican Republic.

Rhythm Biosciences has successfully validated its ColoSTAT® colorectal cancer test, secured its first strategic partnership for Genetype, and secured $1 million in non-dilutive funding, setting the stage for a transformative FY26.

Enlitic, Inc. has confirmed its commitment to achieving operational cashflow break-even by the end of 2025, alongside maintaining its revenue guidance of US$9-11 million for the calendar year.